In conclusion, our model predicts MGMT promoter methylation status based on tumor texture features on gadolinium-enhanced T1-weighted MRI in patients with recurrent glioblastoma treated with alkylating chemotherapy. The gene discussed is MGMT; the disease is neoplasm.